Document Detail


Atypical antipsychotics in children with pervasive developmental disorders.
MedLine Citation:
PMID:  17705564     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment of pervasive developmental disorders (PDDs) is a challenging task, which should include behavioral therapy modifications as well as pharmacologic therapy. There has been a lack of data on using medications in children with PDDs until recent years. Within the last 10 years, an increase in clinical research has attempted to provide efficacy and safety data to support the use of medications in children with PDDs. Double-blinded and open-label research of atypical antipsychotics has been of particular focus. Evidence shows that atypical antipsychotics (AAs) may be useful in treating certain symptoms associated with PDDs, such as aggression, irritability, and self-injurious behavior. This article reviews the literature regarding the use of AAs in children with PDDs. Of the AAs, risperidone has the largest amount of evidence with five published double-blinded, placebo-controlled trials and nine open-label trials. These risperidone trials have consistently shown improvements in aggression, irritability, self-injurious behavior, temper tantrums, and quickly changing moods associated with autistic disorder and other PDDs. Data for the other AAs are limited, but ziprasidone and aripiprazole appear to be promising treatment options. Based on clinical trials, olanzapine and quetiapine have shown minimal clinical benefit and a high incidence of weight gain and sedation. It should be noted that all AAs do have a risk of metabolic syndrome, and patients should be monitored appropriately while receiving these medications. Overall, AAs can be beneficial in alleviating behavioral symptoms, and should be considered an appropriate therapeutic option, as part of a comprehensive treatment strategy, for children with PDD.
Authors:
Benjamin Chavez; Mapy Chavez-Brown; Michael A Sopko; Jose A Rey
Related Documents :
21408084 - Is economic growth associated with reduction in child undernutrition in india?
21318394 - Follow up of children with autism spectrum disorders: stability and change in diagnosis.
10834464 - Compulsive-like behavior in individuals with down syndrome: its relation to mental age ...
21519274 - New ideas in the cause of bladder dysfunction in children.
15602724 - Reduced nasal il-10 and enhanced tnfalpha responses during rhinovirus and rsv-induced u...
11706864 - Executive function deficits in non-retarded autistic children.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Paediatric drugs     Volume:  9     ISSN:  1174-5878     ISO Abbreviation:  Paediatr Drugs     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-20     Completed Date:  2007-11-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100883685     Medline TA:  Paediatr Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  249-66     Citation Subset:  IM    
Affiliation:
Rutgers, State University of New Jersey, Piscataway, New Jersey, USA. bchavez@rci.rutgers.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antipsychotic Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Child
Child Development Disorders, Pervasive / complications,  drug therapy*,  epidemiology
Child, Preschool
Comorbidity
Controlled Clinical Trials as Topic
Dopamine / metabolism
Female
Humans
Male
Norepinephrine / metabolism
Serotonin / metabolism
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 50-67-9/Serotonin; 51-41-2/Norepinephrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management of childhood malignant peripheral nerve sheath tumor.
Next Document:  Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale.